A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

A Phase 1, Cross-Over, Single-Dose, Open-Label Study to Estimate the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 Under Fed and Fasted Conditions in Healthy Adult Subjects

The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.

Inclusion Criteria:

• Male or female of non-childbearing potential

Exclusion Criteria:

• Evidence of clinically-significant medical illness, history of seizures, any condition possibly affecting drug absorption